But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

This weekend’s oncology conference will feature at least 30 different ADC projects.

The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?

A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.